Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas

Clinical Lymphoma, Myeloma and Leukemia

Volumn 16, Issue 8, 2016, Pages 429-433

  Malysz, Jozef ^a   Erdman, Patrick ^a   Klapper, Jeremy ^c   Zhu, Junjia ^b   Creer, Michael ^a   Bayerl, Michael G ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c University of Pittsburgh Medical Center   (United States)

Author keywords

Brentuximab; CD30 immunohistochemical stain; relapsed refractory disease; scoring system; Targeted therapy

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER PROGNOSIS; CANCER RECURRENCE; CELL PROLIFERATION; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE MYC; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; VIRUS EXPRESSION; AGED; CANCER GRADING; COMPLICATION; DISEASE COURSE; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; GENETICS; LYMPHOMA, B-CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; VIROLOGY;

ADULT; AGED; ANTIGENS, CD30; BIOMARKERS, TUMOR; DISEASE PROGRESSION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM GRADING;

EID: 85008602501     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2016.04.011     Document Type: Article

References (15)

1. 1 Younes, A., CD30-targeted antibody therapy. Curr Opin Oncol 23 (2011), 587–593.
2. 2 Katz, J., Janik, J.E., Younes, A., Brentuximab vedotin (SGN-35). Clin Cancer Res 17 (2011), 6428–6436.
3. + lymphomas. Immunotherapy 3 (2011), 475–485.
4. 4 Haddley, K., Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma. Drugs Today (Barc) 48 (2012), 259–270.
5. 5 Swerdlow, S.H., Campo, E., Harris, N.L., et al. (eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tisues, 2008, International Agency for Research on Cancer, Lyon.
6. 6 Hu, S., Xu-Monette, Z.Y., Balasubramanyam, A., et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121 (2013), 2715–2724.
7. 7 Maes, B., Anastasopoulou, A., Kluin-Nelemans, J.C., et al. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features. Ann Oncol 12 (2001), 853–858.
8. 8 Wong, H.W., Wang, J., Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly. Leuk Lymphoma 50 (2009), 335–340.
9. 9 Dojcinov, D., Venkataraman, G., Pittaluga, S., et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hypeplasia and lymphoma. Blood 117 (2011), 4726–4735.
10. 10 Campuzano-Zuluaga, G., Cioffi-Lavina, M., Lossos, I.S., et al. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. Leuk Lymphoma 54 (2013), 2405–2411.
11. 11 Tao, K., Zhu, X., Xu, W., et al. A clinicopathologic and immunohistochemical study of diffuse large B-cell lymphoma. Zhongua Bing Li Xue Za Zhi 31 (2002), 112–115.
12. 12 Eow, G.I., Kim, L.H., Peh, S.C., The pattern of CD15, CD30 and BCL-2 expression in diffuse large B-cell lymphoma. Med J Malaysia 61 (2006), 416–421.
13. 13 Harvey, J.M., Clark, G.M., Osborne, C.K., Allred, D.C., Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligant-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. J Clin Oncol 17 (1999), 1474–1481.
14. 14 Gandhi, S., Gupta, N., Brentuximab vendotin and diffuse large B-cell lymphoma. J Hematol Thromb Dis, 3, 2015, 183.
15. 15 Eric, D., Jacobsen, E.D., Sharman, J.P., et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 125 (2015), 1394–1402.